About Atelerix
Atelerix is a Healthcare company based in Newcastle Upon Tyne (United Kingdom) founded in 2017 by Steve Swioklo. It operates as a technology for cell storage and transportation is developed. It operates on a Product-as-a-Service and Direct-to-Consumer (D2C) model. Atelerix has raised $2.43 million across 8 funding rounds from investors including Gov.uk, Newable and Oxford Technology. The company has 9 employees. Its chief executive is Mick McLean. Atelerix offers products and services including Hypothermic Hydrogel Preservation, Leukapheresis Material Preservation, and Primary Tissue Preservation. Its focus areas include Biotechnology and Cell Preservation. Its legal entity is Atelerix Ltd. Its competitors include Brooks Automation, Bridge to Life, Hemanext, Cellbox Solutions and Cold Chain Technologies and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
Atelerix Ltd is engaged in the development of hypothermic hydrogel-based technology for the preservation of live cells, tissues, and viruses at room temperature. The company operates within the biotechnology sector, offering sustainable and cost-effective solutions for biological transport. Their products cater to various applications, including leukapheresis material, primary tissues, organoids, and microtissues. Emphasis is placed on eco-friendly practices, utilizing natural biopolymers and animal-free materials to reduce carbon footprints in logistics.
- Headquarters Newcastle Upon Tyne, United Kingdom
- Employees 9
- Founders Steve Swioklo
- SectorsHealthcare
- Email••••••••
- Website atelerix.co.uk
- Social LinkedIn X
- Legal Name Atelerix Ltd
- Total Equity Funding$2.43M (USD)
in 8 rounds
- Latest Funding Round$935.51K (USD), Seed
Jan 2025
- InvestorsGov.uk
& 7 more
- Employee Count9
Products & Services of Atelerix
Atelerix offers a comprehensive portfolio of products and services, including Hypothermic Hydrogel Preservation, Leukapheresis Material Preservation, and Primary Tissue Preservation.
Cells and tissues are preserved using hypothermic hydrogel technology.
Leukapheresis materials are preserved for research and medical use.
Primary tissues are maintained fresh without cryogenic freezing methods.
Funding Insights of Atelerix
Atelerix has successfully raised a total of $2.43M across 8 strategic funding rounds. The most recent funding activity was a Seed round of $935.51 thousand completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.43M
- Total Rounds 8
- Last Round Seed — $935,513
- First Round $30,670
(Jun 2017)
- Investors Count 8
All 8 funding rounds of Atelerix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $935,513 | Seed | – | – | |
| Jan 2023 | – | Seed | – | Mandashi | – |
| Feb 2022 | $576,584 | Grant | – | – | |
| Sep 2020 | – | Grant | – | – | |
| Jun 2020 | $62,148 | Grant | – | – | |
| May 2019 | $910,515 | Seed | – | UK Innovation Science & Seed Fund | |
| Apr 2018 | $585,531 | Seed | – | UK Innovation Science & Seed Fund | |
| Jun 2017 | $30,670 | Debt – Conventional | – | – |
8 investors in total: 8 institutional.
Investors in Atelerix
Atelerix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, Newable and Oxford Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on angel investments | – | acfinvestors.com | Sheffield, United Kingdom | |
- | – | mandashi.com | - | |
Early-stage innovations are funded by UKI2S across key sectors. | – | ukinnovationscienceseedfund.co.uk | Manchester, United Kingdom | |
Early-stage micro-VC investments are focused on UK companies. | 1983 | oxfordtechnology.com | - | |
Invests in biotech therapeutics and AI technologies through EIS funds. | 2014 | o2hventures.com | Cambridge, United Kingdom | |
- | – | innovateuk.gov.uk | - | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
Business loans are provided to UK enterprises by Newable. | 1982 | newable.co.uk | London, United Kingdom |
Investor details for Atelerix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Atelerix
6 people are tracked at Atelerix (3 in leadership, 1 in board & advisors, 2 in team); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Steve Swioklo | Co-Founder | Leadership |
Mick McLean | Co-CEO | Leadership |
Andrew Muir | Director | Leadership |
Clive Stanway | Non-Executive Director | Board & advisors |
Jon Bethel | Laboratory Manager | Team |
Debra Leeves | Executive Chair | Team |
Complete people profiles for Atelerix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Atelerix
3 dated milestones of Atelerix across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Atelerix is founded.
- Funding First funding round of $31K.
- Funding Latest funding round, Seed, of $936K.
Competitors of Atelerix
Atelerix has 9 listed competitors in our database, 6 of them funded. They include Brooks Automation, Bridge to Life, Hemanext, Cellbox Solutions and Cold Chain Technologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| brooks.com | 1978 | Chelmsford, United States | – | 1,928 | Vacuum robots for semiconductor wafer handling are developed. | |
| bridgetolife.com | 2012 | Columbia, United States | $57M | – | Cold storage solutions for organ transplant preservation are provided. | |
| hemanext.com | 2004 | Lexington, United States | $127.57M | 53 | Technologies for blood and product storage are developed. | |
| cellbox-solutions.com | 2016 | Lubeck, Germany | $6.99M | – | Portable devices for cell storage and transport are provided. | |
| coldchaintech.com | 2001 | Franklin, United States | – | – | Thermal packaging solutions and cold chain monitoring services are provided. | |
| biocision.com | 2007 | Larkspur, United States | $11.1M | 48 | Provider of handling, storage and transport solutions for temperature-sensitive biomedical samples and drugs | |
| nectome.com | 2015 | San Francisco, United States | – | – | Brain preservation is achieved through chemical fixation and vitrification techniques. | |
| genepoint.cn | 2015 | Shanghai, China | $48.3M | – | Platform for cryostorage and long-term biological preservation is provided. | |
| blackfrog.in | 2015 | Manipal, India | $1.97M | 29 | Portable refrigeration systems for biologicals cold-chain transport are provided. |
Detailed competitors of Atelerix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Atelerix
The website of Atelerix (atelerix.co.uk) receives about 1K visits a month.
- Monthly visits1K
▲ 216% vs previous month
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Atelerix (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Atelerix
Complete news archive for Atelerix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atelerix
Atelerix was founded in 2017.
Atelerix is headquartered in Newcastle Upon Tyne, United Kingdom.
Mick McLean is the current CEO of Atelerix.
Atelerix is a funded company, having raised a total of $2.43M across 8 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $30.67K, raised on Jun 2017.
Atelerix has 9 employees.
Atelerix Ltd is engaged in the development of hypothermic hydrogel-based technology for the preservation of live cells, tissues, and viruses at room temperature. The company operates within the biotechnology sector, offering sustainable and cost-effective solutions for biological transport. Their products cater to various applications, including leukapheresis material, primary tissues, organoids, and microtissues. Emphasis is placed on eco-friendly practices, utilizing natural biopolymers and animal-free materials to reduce carbon footprints in logistics.
Atelerix's top competitors include Brooks Automation, Hemanext and Bridge to Life.
Atelerix offers Hypothermic Hydrogel Preservation, Leukapheresis Material Preservation, and Primary Tissue Preservation.
Atelerix has 8 investors. Key investors include Gov.uk, Newable, Oxford Technology, ACF Investors, and o2h ventures.
Atelerix operates through Atelerix Ltd.